<img alt="" height="1" width="1" />
Orexigen puts obesity drug development on hold
Orexigen Therapeutics Inc. said Friday that US regulators are making "unprecedented" demands about safety trials for its obesity drug candidate Contrave, and it is putting on hold further work on securing approval in that market. ...
Drug Maker Withdraws Bid for Obesity Drug ApprovalNew York Times
Orexigen To Halt US Obesity Program As It Disputes FDA Contrave RequestWall Street Journal
Orexigen Falls After Halting Development of Diet Pill in U.S.Bloomberg
Telegraph-Journal (registration) -FierceBiotech -MarketWatch
all 252 news articles &raquo;